News from Portfolio Companies

  • New Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPO
    June 30, 2020  |  VIRGINIA BEACH, Va., June 30, 2020 /PRNewswire/ — New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of its portfolio company, ADC Therapeutics (NYSE:ADCT). The company raised $267.6 million through the sale of 14,082,475 of its common shares priced at $19.00 per share.
  • New Ventures Portfolio Company, Royalty Pharma, Surges On Public Debut
    June 25, 2020  |  VIRGINIA BEACH, Va., June 25, 2020 /PRNewswire/ — New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of one of its portfolio companies, Royalty Pharma (NASDAQ:RPRX).
  • ROYALTY PHARMA ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING
    NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ: RPRX) today announced the closing of the initial public offering of 89,333,920 shares of its Class A ordinary shares pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”) at a price to the public of $28.00 per share.
    June 19, 2020  | 
  • Royalty Pharma surges in trading debut, marking biggest US IPO of the year
    June 17, 2020  |  Royalty Pharma’s stock jumped nearly 60% in its Nasdaq trading debut Tuesday as biotech initial public offerings continue to dominate this year. Shares in the company closed at $44.50, valuing the company at $26.5 billion. Royalty Pharma’s IPO was the largest on a US exchange so far this year, according to PitchBook data.
  • ROYALTY PHARMA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
    NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc today announced the pricing of the initial public offering of 77,681,670 shares of its Class A ordinary shares pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”) at a price to the public of $28.00 per share.
    June 16, 2020  | 
  • ROYALTY PHARMA FILES REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING
    NEW YORK (NY), May 23, 2020 – Royalty Pharma plc today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to its proposed initial public offering of its Class A ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.
    June 5, 2020  | 
  • ADC THERAPEUTICS ANNOUNCES LONCASTUXIMAB TESIRINE (LONCA) CLINICAL DATA TO BE PRESENTED AT THE VIRTUAL 25TH EHA ANNUAL CONGRESS
    Interim results of pivotal Phase 2 trial reinforce potential of Lonca to become a key part of the treatment paradigm for patients with relapsed or refractory diffuse large B-cell lymphoma Interim results of Phase 1/2 trial highlight potential to advance Lonca into earlier lines of therapy in combination with other therapies
    June 5, 2020  | 
  • ADC THERAPEUTICS ANNOUNCES CLOSING OF UPSIZED $267 MILLION INITIAL PUBLIC OFFERING AND RECEIPT OF THE $65 MILLION FIRST TRANCHE UNDER ITS $115 MILLION CONVERTIBLE CREDIT FACILITY WITH DEERFIELD
    June 5, 2020  |  MAY, 19, 2020 LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today the closing of its initial public offering of 14,082,475 shares of its common shares at a price of $19.00 per ...
  • ADC Therapeutics Announces Launch of Initial Public Offering
    Lausanne, Switzerland — May 11, 2020 — ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that it has launched the initial public offering of 7,355,000 shares of its common shares. In addition, ADC Therapeutics has granted the underwriters an option to purchase up to 1,103,250 additional common shares. The initial public offering price is expected to be between $16.00 and $18.00 per common share. The common shares have been approved for listing on the New York Stock Exchange under the ticker symbol “ADCT.”
    June 4, 2020  | 
  • ADC THERAPEUTICS ANNOUNCES A $115 MILLION CONVERTIBLE CREDIT FACILITY WITH DEERFIELD
    Lausanne, Switzerland, May 1, 2020 – ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, today announced that it entered into a $115 million Convertible Credit Facility (the “Convertible Credit Facility”) with funds affiliated with Deerfield Management Company, L.P. (collectively, “Deerfield”).  
    June 4, 2020  |   

New Ventures News and Publications

  • Covid-19 Tracing Inside Companies, with SaferMe’s Clint Van Marrewijk
    Episode Summary Harry’s guest this week is the founder and CEO of a New Zealand firm, SaferMe, that had developed proximity-based smartphone apps for worker safety. When the coronavirus came along, their apps turned out to be a great way to help companies build their own “contact tables” to identify, test, and isolate SARS-CoV-2 carriers. Episode Notes Harry’s guest this ...
  • Ulo Palm on P-Values: What They Are and Why They’re Past Their Prime
    Episode Summary This week Harry quizzes Ulo Palm, the senior vice president of digital sciences at Allergan, about the long and problematic reign of the p-value in statistical analysis, and why it may be time for the biopharma industry to look to more nuanced measures of whether a drug trial succeeded. Episode Notes Though the p-value “determines everything we do ...
  • Enterin to Conduct a Randomized Phase 1/2a Study in Hospitalized Patients With COVID-19
    PHILADELPHIA, April 17, 2020 /PRNewswire/ — Enterin, Inc., a clinical-stage company focused on neurodegenerative diseases, announced today that it has received feedback from the FDA laying out the path for a Phase 1/2a study in hospitalized patients with COVID-19 infection. The study will involve 10 U.S. sites and will enroll 80 hospitalized patients. Patients will have been diagnosed with SARS-CoV-2, have an SpO2 ...
  • How Data Is Critical to Engineering Antibodies to Block COVID-19
    Episode Summary Distributed Bio aims to use its computational antibody engineering platform to identify antibodies that protect against SARS and optimize them to block the SARS-CoV2 coronavirus. This week Harry gets an progress update from three key Distributed Bio scientists. Episode Notes Building on his March 2020 interview with Jake Glanville, the founding partner and CEO of South San Francisco-based ...
  • Jacob Glanville Confronts Coronavirus Through Immuno-engineering
    Episode Summary Harry’s guest for this unusually frank and urgent episode is Jacob Glanville, the founding partner, CEO, and president of Distributed Bio. The company is using its skills in computational antibody analysis and optimization to help the drug industry develop new vaccines and antibody-based treatments for a range of diseases, potentially including the coronavirus that causes COVID-19. Episode Notes ...
  • Ramy Farid on the Power of Computation in Drug Discovery
    Episode Summary Harry interviews Ramy Farid, president and CEO of Schrödinger Pharmaceuticals, about the company’s success using chemical simulation software to help drug makers zero in on promising drug candidates—and about its recent IPO, which brought in more than twice as much cash as the company expected. Episode Notes Schrödinger makes software that models the physics of atomic-scale interactions to ...
  • Illumina’s Phil Febbo on Sequencing, Coronavirus and Viral Outbreaks
    Episode Summary As the Wuhan coronavirus outbreak spreads in Asia, Harry speaks with Phil Febbo, the chief medical officer of Illumina, one of the world’s largest makers of equipment for high-throughput DNA sequencing. Febbo highlights sequencing’s emerging contribution to the understanding and treatment of infectious disease. Episode Notes Rapid sequencing of viral genomes is giving physicians and epidemiologists new ways ...
  • Daniella Gilboa on How Deep Learning Can Revolutionize IVF
    Episode Summary: Daniella Gilboa is an embryologist in Israel working to bring the power of AI and machine learning to the embryo selection phase of IVF treatment. She explains how her new startup aims to automate this error-ridden process, raising efficiency and lowering the overall cost of IVF. Episode Notes: Doctors helping couples conceive through in-vitro fertilization typically must screen ...
  • Drug developers take fresh aim at ‘guided-missile’ cancer drugs
    John Miller Ludwig Burger Published: Jan 06 at 11:08 a.m. By Ludwig Burger and John Miller FRANKFURT/ZURICH (Reuters) – Dozens of drugmakers are conducting human trials for a record 89 therapies that pair antibodies with toxic agents to fight cancer, evidence of renewed confidence in an approach that has long fallen short of its promise, an analysis compiled for Reuters shows. ...
  • Tom Davenport on the Analytics Gap in Healthcare
    Episode Summary Harry’s guest this week is Tom Davenport, who argues that the healthcare industry is way behind in its use of big-data analytics software to make smarter decisions about business and patient care. “This is a period of lots of opportunity to use new technologies to change healthcare, and God knows we need it, from a value-for-expense standpoint,” Davenport ...